MoonLake Immunotherapeutics (MLTX) has a current Price-to-Book (P/B) ratio of 2.64. Compared to its 3-year average P/B ratio of 7.95, the current P/B ratio is approximately -66.86% higher. Relative to its 5-year average P/B ratio of 6.76, the current P/B ratio is about -61.03% higher. MoonLake Immunotherapeutics (MLTX) has a Forward Free Cash Flow (FCF) yield of approximately -21.80%. Compared to its 3-year average FCF yield of -5.06%, the current FCF yield is approximately 330.76% lower. Relative to its 5-year average FCF yield of -8.14%, the current FCF yield is about 167.89% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MLTX competitors is 533.49, providing a benchmark for relative valuation. MoonLake Immunotherapeutics Corp (MLTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MLTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MLTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MLTX currently overvalued or undervalued?

What is MoonLake Immunotherapeutics (MLTX) fair value?

MLTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of MoonLake Immunotherapeutics (MLTX) is between to according to relative valuation method.

How does MLTX's valuation metrics compare to the industry average?

The average P/S ratio for MLTX's competitors is 533.49, providing a benchmark for relative valuation. MoonLake Immunotherapeutics Corp (MLTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for MoonLake Immunotherapeutics (MLTX) as of Mar 03 2026?

As of Mar 03 2026, MoonLake Immunotherapeutics (MLTX) has a P/B ratio of 2.64. This indicates that the market values MLTX at 2.64 times its book value.

What is the current FCF Yield for MoonLake Immunotherapeutics (MLTX) as of Mar 03 2026?

As of Mar 03 2026, MoonLake Immunotherapeutics (MLTX) has a FCF Yield of -21.80%. This means that for every dollar of MoonLake Immunotherapeutics's market capitalization, the company generates -21.80 cents in free cash flow.

What is the current Forward P/E ratio for MoonLake Immunotherapeutics (MLTX) as of Mar 03 2026?

As of Mar 03 2026, MoonLake Immunotherapeutics (MLTX) has a Forward P/E ratio of -3.24. This means the market is willing to pay $-3.24 for every dollar of MoonLake Immunotherapeutics's expected earnings over the next 12 months.

What is the current Forward P/S ratio for MoonLake Immunotherapeutics (MLTX) as of Mar 03 2026?

As of Mar 03 2026, MoonLake Immunotherapeutics (MLTX) has a Forward P/S ratio of 0.00. This means the market is valuing MLTX at $0.00 for every dollar of expected revenue over the next 12 months.

MLTX Valuation